Iovance Biotherapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

Iovance Biotherapeutics

07/08/2024 03:07

* Iovance Biotherapeutics Inc  IOVA.OQ   IOVA.O  is expected
to show a rise in quarterly revenue when it reports  results on
August 8 for the period ending June 30 2024
    * The San Carlos California-based  company is expected to
report a
10,231.1% increase in revenue to $24.588 million from $238
thousand a year ago, according to the mean estimate from 12
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Iovance Biotherapeutics
Inc is
for a loss of 35 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Iovance
Biotherapeutics Inc is $25.00​, above​ its last closing price
of $7.74. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.42       -0.42      -0.42     Met     0.6
 Dec. 31 2024  -0.43       -0.43      -0.45     Missed  -4.3
 Sep. 30 2023  -0.46       -0.45      -0.46     Missed  -1.3​
 Jan. 1 0001   -0.82       -0.80      -0.47     Beat    41
 ​​Mar.        -0.77                  -0.50             32.9
 31 2023                                                
 Dec. 31 2022  -0.63       -0.64      -0.64     Met     -0.4​
 Jan. 1 0001   -0.63       -0.64      -0.63     Beat    1.2
 Jun. 30 2022  -0.59       -0.61      -0.63     Missed  -3.9
 This summary was machine generated August 7 at 02:07 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)